Lonza investing 200 million francs in new manufacturing complex

23 April 2021

Swiss contract development and manufacturing organization (CDMO) Lonza (SIX: LONN) today announced the construction of a new small molecule manufacturing complex at its Visp (CH) site.

The new manufacturing complex will occupy an overall footprint of around 2,000 m2 with six levels of manufacturing space, and involves at investment of 200 million Swiss francs ($218 million).

The complex will offer several opportunities for future expansions supporting the small molecules technologies offering, which include drug substance, particle engineering technologies such as spray drying dispersion, and drug product.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK